The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol
Open Access
- 3 July 2020
- journal article
- research article
- Published by Elsevier BV in Engineering
- Vol. 6 (10), 1199-1204
- https://doi.org/10.1016/j.eng.2020.06.011
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirusJournal of Biological Chemistry, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Drug treatment options for the 2019-new coronavirus (2019-nCoV)BioScience Trends, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routesEmerging Microbes & Infections, 2020
- Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infectionsKazan medical journal, 2018
- [Investigation of Prophylactic Efficacy of Triazavirin Against Experimental Forest- Spring Encephalitis on Albino Mice].2015
- Antiviral Properties, Metabolism, and Pharmacokinetics of a Novel Azolo-1,2,4-Triazine-Derived Inhibitor of Influenza A and B Virus ReplicationAntimicrobial Agents and Chemotherapy, 2010